PLUS1
102.65
-4.39 (-4.1%)
-4.39 (-4.1%)
Upgrade to Real-Time
Afterhours
Best deals to access real time data! |
|
Ultimate Trader (Monthly)
Monthly Subscription
for only
|
|
Small Cap Basic
Monthly Subscription
for only
|
|
Big Cap Pro
Monthly Subscription
for only
|
|
VAT not included
|
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Novavax Inc | NVAX | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded  |
|
|---|---|---|---|---|
| -4.39 | -4.1% | 102.65 | 17:44:03 |
| Close Price | Low Price | High Price | Open Price | Previous Close |
|---|---|---|---|---|
| 102.05 | 100.3728 | 108.20 | 107.80 | 107.04 |
| Bid Price | Ask Price | Spread | News | |
|---|---|---|---|---|
| 102.47 | 103.00 | 0.53 | - | - |
| Stock Trades | Traded Volume | VWAP | Dollar Volume | Average Volume | 52 Week Range |
|---|---|---|---|---|---|
| 36,711 | 2,704,388 | $ 102.97 | $ 278,468,507 | 4,354,214 | 3.54 - 198.50 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 17:43:55 | 5 | $ 102.97 | USD |
Novavax Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| $ 6.29B | 61.28M | 59.04M | $ 18.66M | $ - | -5.62 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | $ - | 0.00% | - | - |
Novavax News
| Date | Time | Source | News Article |
|---|---|---|---|
| 10/13/2020 | 08:00 | GlobeNewswire Inc. | Novavax Appoints Leadership Team to Advance NanoFlu through.. |
| 10/08/2020 | 09:29 | Dow Jones News | Covid-19 Vaccine-Trial Volunteers Look to Make a Difference |
| 10/05/2020 | 09:00 | GlobeNewswire Inc. | Novavax to Participate in Upcoming Conferences |
| 10/01/2020 | 17:41 | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) |
| 10/01/2020 | 17:40 | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) |
| 9/29/2020 | 19:05 | ADVFN Crypto NewsWire | The 'Data is the New Oil' Thematic Investment Basket:.. |
| 9/29/2020 | 18:17 | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) |
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical NVAX Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 111.25 | 121.92 | 100.3728 | 112.59 | 2,611,140 | -8.60 | -7.73% |
| 1 Month | 102.49 | 121.92 | 96.48 | 109.39 | 3,259,385 | 0.16 | 0.16% |
| 3 Months | 134.40 | 198.50 | 83.22 | 126.79 | 5,895,689 | -31.75 | -23.62% |
| 6 Months | 19.10 | 198.50 | 16.41 | 84.07 | 7,800,067 | 83.55 | 437.43% |
| 1 Year | 4.47 | 198.50 | 3.54 | 55.32 | 6,442,613 | 98.18 | 2,196.42% |
| 3 Years | 20.20 | 198.50 | 3.54 | 37.57 | 6,762,167 | 82.45 | 408.17% |
| 5 Years | 155.40 | 198.50 | 3.54 | 47.54 | 7,011,128 | -52.75 | -33.94% |
Novavax Description
| Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. Novavax works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. Novavax develops product candidates geared toward all age demographics of the general population. |
